Human Gene CCND1 (ENST00000227507.3_4) from GENCODE V47lift37
  Description: cyclin D1 (from RefSeq NM_053056.3)
Gencode Transcript: ENST00000227507.3_4
Gencode Gene: ENSG00000110092.4_7
Transcript (Including UTRs)
   Position: hg19 chr11:69,455,924-69,469,242 Size: 13,319 Total Exon Count: 5 Strand: +
Coding Region
   Position: hg19 chr11:69,456,082-69,466,050 Size: 9,969 Coding Exon Count: 5 

Page IndexSequence and LinksUniProtKB CommentsPrimersMalaCardsCTD
Gene AllelesRNA-Seq ExpressionMicroarray ExpressionRNA StructureProtein StructureOther Species
GO AnnotationsmRNA DescriptionsPathwaysOther NamesModel InformationMethods
Data last updated at UCSC: 2024-08-22 23:36:26

-  Sequence and Links to Tools and Databases
 
Genomic Sequence (chr11:69,455,924-69,469,242)mRNA (may differ from genome)Protein (295 aa)
Gene SorterGenome BrowserOther Species FASTAVisiGeneGene interactionsTable Schema
AlphaFoldBioGPSEnsemblEntrez GeneExonPrimerGeneCards
HGNCMalacardsMGIOMIMPubMedUniProtKB
WikipediaBioGrid CRISPR DB

-  Comments and Description Text from UniProtKB
  ID: Q6FI00_HUMAN
DESCRIPTION: SubName: Full=CCND1 protein; SubName: Full=Cyclin D1 (PRAD1: parathyroid adenomatosis 1); SubName: Full=Cyclin D1, isoform CRA_c; SubName: Full=cDNA, FLJ93625, Homo sapiens cyclin D1 (PRAD1: parathyroid adenomatosis 1) (CCND1),mRNA;
SIMILARITY: Belongs to the cyclin family.

-  Primer design for this transcript
 

Primer3Plus can design qPCR Primers that straddle exon-exon-junctions, which amplify only cDNA, not genomic DNA.
Click here to load the transcript sequence and exon structure into Primer3Plus

Exonprimer can design one pair of Sanger sequencing primers around every exon, located in non-genic sequence.
Click here to open Exonprimer with this transcript

To design primers for a non-coding sequence, zoom to a region of interest and select from the drop-down menu: View > In External Tools > Primer3


-  MalaCards Disease Associations
  MalaCards Gene Search: CCND1
Diseases sorted by gene-association score: chronic lymphocytic leukemia* (499), multiple myeloma* (438), von hippel-lindau syndrome* (389), mantle cell lymphoma* (290), colorectal cancer* (132), hairy cell leukemia (43), lymphoma (27), plasma cell leukemia (26), parathyroid adenoma (24), squamous cell carcinoma (20), parathyroid carcinoma (19), retinoblastoma (17), breast cancer (17), salivary gland adenoid cystic carcinoma (17), esophageal cancer (15), b-cell lymphomas (14), prolymphocytic leukemia (14), extramedullary plasmacytoma (13), bowenoid papulosis (13), adenoma (13), follicular lymphoma (12), pancreatic cancer (12), lung cancer (12), hepatocellular carcinoma (11), lymphoma, small cleaved-cell, diffuse (11), breast ductal carcinoma (11), lymphoma, non-hodgkin (11), bile duct carcinoma (11), oral squamous cell carcinoma (11), endometrial cancer (10), oral cancer (10), atypical teratoid rhabdoid tumor (10), malignant iris melanoma (10), estrogen-receptor positive breast cancer (10), familial adenomatous polyposis (10), glioma (9), squamous cell carcinoma, head and neck (9), hemimegalencephaly (9), astrocytoma (9), larynx cancer (9), star syndrome (9), retinal cancer (8), sensory system cancer (8), lymphoma, malt, somatic (8), bladder urothelial carcinoma (8), squamous cell carcinoma of the oral tongue (8), verrucous carcinoma (8), breast papillomatosis (8), hyperparathyroidism-jaw tumor syndrome (7), ductal carcinoma in situ (7), thyroid cancer (7), barrett esophagus/esophageal adenocarcinoma (7), stomach cancer (7), polymorphous low-grade adenocarcinoma (7), adenocarcinoma (7), hidradenocarcinoma (6), gallbladder cancer (6), tongue cancer (6), cll/sll (6), small intestine cancer (6), plasmacytoma (6), chondromyxoid fibroma (6), ocular cancer (6), endometrial stromal sarcoma (6), inflammatory myofibroblastic tumor (6), ethmoid sinus cancer (5), ethmoid sinus adenocarcinoma (5), jejunal adenocarcinoma (5), skin carcinoma in situ (5), superficial urinary bladder cancer (5), prostate lymphoma (5), non-proliferative fibrocystic change of the breast (5), adenomatous polyposis coli (5), nervous system cancer (5), gastrointestinal system benign neoplasm (5), pharynx cancer (5), marginal zone b-cell lymphoma (5), synchronous bilateral breast carcinoma (5), prostate cancer (5), endometrial squamous cell carcinoma (5), balanitis xerotica obliterans (5), mutagen sensitivity (5), gastrointestinal system cancer (5), glioblastoma multiforme (5), keratocystic odontogenic tumor (4), ischemic fasciitis (4), intestinal benign neoplasm (4), pre-malignant neoplasm (4), clear cell renal cell carcinoma (4), lymph node cancer (4), melanoma (3), ovarian cancer, somatic (3), urinary bladder cancer (3), diffuse large b-cell lymphoma (3), pancreatic ductal adenocarcinoma (2), intrahepatic cholangiocarcinoma (2), lung cancer susceptibility 3 (2), papilloma (2), lynch syndrome (2), bladder cancer, somatic (2), adamantinoma of long bones (2), ewing sarcoma (2), cell type cancer (1), reproductive organ cancer (1), female reproductive organ cancer (1), cell type benign neoplasm (1), male reproductive organ cancer (1), gastric cancer, somatic (1)
* = Manually curated disease association

-  Comparative Toxicogenomics Database (CTD)
  The following chemicals interact with this gene           more ... click here to view the complete list

+  Common Gene Haplotype Alleles
  Press "+" in the title bar above to open this section.

-  RNA-Seq Expression Data from GTEx (53 Tissues, 570 Donors)
  Highest median expression: 66.79 RPKM in Cells - Cultured fibroblasts
Total median expression: 523.67 RPKM



View in GTEx track of Genome Browser    View at GTEx portal     View GTEx Body Map

+  Microarray Expression Data
  Press "+" in the title bar above to open this section.

-  mRNA Secondary Structure of 3' and 5' UTRs
 
RegionFold EnergyBasesEnergy/Base
Display As
5' UTR -59.00158-0.373 Picture PostScript Text
3' UTR -1013.303192-0.317 Picture PostScript Text

The RNAfold program from the Vienna RNA Package is used to perform the secondary structure predictions and folding calculations. The estimated folding energy is in kcal/mol. The more negative the energy, the more secondary structure the RNA is likely to have.

-  Protein Domain and Structure Information
  InterPro Domains: Graphical view of domain structure
IPR013763 - Cyclin-like
IPR014400 - Cyclin_A/B/D/E
IPR004367 - Cyclin_C
IPR006671 - Cyclin_N

Pfam Domains:
PF00134 - Cyclin, N-terminal domain
PF02984 - Cyclin, C-terminal domain

SCOP Domains:
47954 - Cyclin-like

ModBase Predicted Comparative 3D Structure on Q6FI00
FrontTopSide
The pictures above may be empty if there is no ModBase structure for the protein. The ModBase structure frequently covers just a fragment of the protein. You may be asked to log onto ModBase the first time you click on the pictures. It is simplest after logging in to just click on the picture again to get to the specific info on that model.

-  Orthologous Genes in Other Species
  Orthologies between human, mouse, and rat are computed by taking the best BLASTP hit, and filtering out non-syntenic hits. For more distant species reciprocal-best BLASTP hits are used. Note that the absence of an ortholog in the table below may reflect incomplete annotations in the other species rather than a true absence of the orthologous gene.
MouseRatZebrafishD. melanogasterC. elegansS. cerevisiae
No orthologNo orthologNo orthologNo orthologNo orthologNo ortholog
Gene DetailsGene Details    
Gene SorterGene Sorter    
 RGDEnsembl   
      
      

-  Gene Ontology (GO) Annotations with Structured Vocabulary
  Molecular Function:
GO:0004672 protein kinase activity
GO:0016301 kinase activity
GO:0016538 cyclin-dependent protein serine/threonine kinase regulator activity
GO:0019901 protein kinase binding
GO:0044877 macromolecular complex binding

Biological Process:
GO:0000082 G1/S transition of mitotic cell cycle
GO:0000320 re-entry into mitotic cell cycle
GO:0001889 liver development
GO:0006468 protein phosphorylation
GO:0007049 cell cycle
GO:0007595 lactation
GO:0008284 positive regulation of cell proliferation
GO:0010033 response to organic substance
GO:0010039 response to iron ion
GO:0010165 response to X-ray
GO:0010243 response to organonitrogen compound
GO:0014070 response to organic cyclic compound
GO:0016055 Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030857 negative regulation of epithelial cell differentiation
GO:0030968 endoplasmic reticulum unfolded protein response
GO:0031100 animal organ regeneration
GO:0032026 response to magnesium ion
GO:0032355 response to estradiol
GO:0033197 response to vitamin E
GO:0033327 Leydig cell differentiation
GO:0033598 mammary gland epithelial cell proliferation
GO:0033601 positive regulation of mammary gland epithelial cell proliferation
GO:0042493 response to drug
GO:0043627 response to estrogen
GO:0045444 fat cell differentiation
GO:0045471 response to ethanol
GO:0045859 regulation of protein kinase activity
GO:0048545 response to steroid hormone
GO:0051384 response to glucocorticoid
GO:0051412 response to corticosterone
GO:0051592 response to calcium ion
GO:0051726 regulation of cell cycle
GO:0060070 canonical Wnt signaling pathway
GO:0060749 mammary gland alveolus development
GO:0071310 cellular response to organic substance
GO:0097421 liver regeneration
GO:2000045 regulation of G1/S transition of mitotic cell cycle

Cellular Component:
GO:0000307 cyclin-dependent protein kinase holoenzyme complex
GO:0005634 nucleus
GO:0005654 nucleoplasm
GO:0005737 cytoplasm
GO:0005923 bicellular tight junction


-  Descriptions from all associated GenBank mRNAs
  JA488709 - Sequence 2 from Patent EP2350321.
LP882416 - Sequence 11 from Patent WO2017180581.
X59798 - Human PRAD1 mRNA for cyclin.
M73554 - Human bcl-1 mRNA, complete CDS.
BC023620 - Homo sapiens cyclin D1, mRNA (cDNA clone MGC:23386 IMAGE:4650919), complete cds.
AB075505 - Homo sapiens neuroblastoma cDNA, clone:Nbla00347, full insert sequence.
JD299574 - Sequence 280598 from Patent EP1572962.
LY623323 - KR 1020180134347-A/11: DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER.
MB416866 - JP 2019518426-A/6: DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER.
AK313136 - Homo sapiens cDNA, FLJ93625, Homo sapiens cyclin D1 (PRAD1: parathyroid adenomatosis 1) (CCND1),mRNA.
AK299044 - Homo sapiens cDNA FLJ51281 complete cds, highly similar to G1/S-specific cyclin-D1.
Z23022 - H.sapiens of BCL1 mRNA encoding cyclin.
M74092 - Human cyclin mRNA.
BC025302 - Homo sapiens cyclin D1, mRNA (cDNA clone MGC:39267 IMAGE:5457963), complete cds.
M64349 - Human cyclin D (cyclin D1) mRNA, complete cds.
BC000076 - Homo sapiens cyclin D1, mRNA (cDNA clone MGC:2316 IMAGE:3508088), complete cds.
BC001501 - Homo sapiens cyclin D1, mRNA (cDNA clone MGC:2233 IMAGE:3507598), complete cds.
BC014078 - Homo sapiens cyclin D1, mRNA (cDNA clone MGC:20169 IMAGE:4124540), complete cds.
JD077228 - Sequence 58252 from Patent EP1572962.
JD455214 - Sequence 436238 from Patent EP1572962.
JD118113 - Sequence 99137 from Patent EP1572962.
JD104710 - Sequence 85734 from Patent EP1572962.
JD372498 - Sequence 353522 from Patent EP1572962.
AB385148 - Synthetic construct DNA, clone: pF1KB5663, Homo sapiens CCND1 gene for G1/S-specific cyclin-D1, complete cds, without stop codon, in Flexi system.
KJ890761 - Synthetic construct Homo sapiens clone ccsbBroadEn_00155 CCND1 gene, encodes complete protein.
AM393193 - Synthetic construct Homo sapiens clone IMAGE:100001850 for hypothetical protein (CCND1 gene).
AM393430 - Synthetic construct Homo sapiens clone IMAGE:100001931 for hypothetical protein (CCND1 gene).
AM393593 - Synthetic construct Homo sapiens clone IMAGE:100001857 for hypothetical protein (CCND1 gene).
DQ891848 - Synthetic construct clone IMAGE:100004478; FLH180582.01X; RZPDo839D10134D cyclin D1 (CCND1) gene, encodes complete protein.
DQ895038 - Synthetic construct Homo sapiens clone IMAGE:100009498; FLH180578.01L; RZPDo839D10133D cyclin D1 (CCND1) gene, encodes complete protein.
CU692810 - Synthetic construct Homo sapiens gateway clone IMAGE:100021929 5' read CCND1 mRNA.
KJ896486 - Synthetic construct Homo sapiens clone ccsbBroadEn_05880 CCND1 gene, encodes complete protein.
CR542099 - Homo sapiens full open reading frame cDNA clone RZPDo834A1237D for gene CCND1, cyclin D1 (PRAD1: parathyroid adenomatosis 1); complete cds, without stopcodon.
BT019844 - Homo sapiens cyclin D1 (PRAD1: parathyroid adenomatosis 1) mRNA, complete cds.
BT019845 - Homo sapiens cyclin D1 (PRAD1: parathyroid adenomatosis 1) mRNA, complete cds.
CR536538 - Homo sapiens full open reading frame cDNA clone RZPDo834E0520D for gene CCND1, cyclin D1 (PRAD1: parathyroid adenomatosis 1); complete cds, incl. stopcodon.
LQ834722 - Sequence 26 from Patent WO2018134305.
AY830112 - Homo sapiens cyclin D1 (CCND1) mRNA, partial cds.
S71637 - cyclin D1 {3' truncated transcript} [human, breast cancer cell line MDA MB-453, mRNA Partial Mutant, 117 nt].
JD556176 - Sequence 537200 from Patent EP1572962.
JD301486 - Sequence 282510 from Patent EP1572962.
JD167829 - Sequence 148853 from Patent EP1572962.
JD131227 - Sequence 112251 from Patent EP1572962.
JD057695 - Sequence 38719 from Patent EP1572962.
JD098370 - Sequence 79394 from Patent EP1572962.
JD371152 - Sequence 352176 from Patent EP1572962.
JD261602 - Sequence 242626 from Patent EP1572962.
MA264858 - JP 2017508467-A/178: PHARMACEUTICAL COMPOSITIONS COMPRISING RNA AND USE FOR TREATING CANCER.
MS942534 - Sequence 178 from Patent EP3116513.
JD231894 - Sequence 212918 from Patent EP1572962.
JD275312 - Sequence 256336 from Patent EP1572962.
JD235983 - Sequence 217007 from Patent EP1572962.
JD360572 - Sequence 341596 from Patent EP1572962.
JD316127 - Sequence 297151 from Patent EP1572962.
JD387100 - Sequence 368124 from Patent EP1572962.
MA264862 - JP 2017508467-A/182: PHARMACEUTICAL COMPOSITIONS COMPRISING RNA AND USE FOR TREATING CANCER.
MS942538 - Sequence 182 from Patent EP3116513.
JD232915 - Sequence 213939 from Patent EP1572962.
JD391713 - Sequence 372737 from Patent EP1572962.
JD128474 - Sequence 109498 from Patent EP1572962.
MA264864 - JP 2017508467-A/184: PHARMACEUTICAL COMPOSITIONS COMPRISING RNA AND USE FOR TREATING CANCER.
MS942540 - Sequence 184 from Patent EP3116513.
JD132048 - Sequence 113072 from Patent EP1572962.
JD508264 - Sequence 489288 from Patent EP1572962.
JD191189 - Sequence 172213 from Patent EP1572962.
JD406204 - Sequence 387228 from Patent EP1572962.
JD136719 - Sequence 117743 from Patent EP1572962.
JD270790 - Sequence 251814 from Patent EP1572962.
JD190585 - Sequence 171609 from Patent EP1572962.
JD121732 - Sequence 102756 from Patent EP1572962.
JD100650 - Sequence 81674 from Patent EP1572962.
JD045438 - Sequence 26462 from Patent EP1572962.
JD482870 - Sequence 463894 from Patent EP1572962.
JD217646 - Sequence 198670 from Patent EP1572962.
JD195746 - Sequence 176770 from Patent EP1572962.
JD188170 - Sequence 169194 from Patent EP1572962.

-  Biochemical and Signaling Pathways
  BioCarta from NCI Cancer Genome Anatomy Project
h_gsk3Pathway - Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages
h_cellcyclePathway - Cyclins and Cell Cycle Regulation
h_g1Pathway - Cell Cycle: G1/S Check Point
h_wntPathway - WNT Signaling Pathway
h_p53Pathway - p53 Signaling Pathway
h_btg2Pathway - BTG family proteins and cell cycle regulation
h_carm-erPathway - CARM1 and Regulation of the Estrogen Receptor
h_RacCycDPathway - Influence of Ras and Rho proteins on G1 to S Transition

-  Other Names for This Gene
  Alternate Gene Symbols: CCND1 , ENST00000227507.1, ENST00000227507.2, hCG_2016647 , NM_053056, Q6FI00, Q6FI00_HUMAN, uc317dmv.1, uc317dmv.2
UCSC ID: ENST00000227507.3_4
RefSeq Accession: NM_053056.3
Protein: Q6FI00

-  Gene Model Information
  Click here for a detailed description of the fields of the table above.

-  Methods, Credits, and Use Restrictions
  Click here for details on how this gene model was made and data restrictions if any.